Paul Tudor Jones Ventyx Biosciences, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 20,355 shares of VTYX stock, worth $35,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,355
Previous 28,133
27.65%
Holding current value
$35,010
Previous $64,000
31.25%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VTYX
# of Institutions
125Shares Held
52.9MCall Options Held
35.3KPut Options Held
83K-
Deerfield Management Company, L.P. (Series C) New York, NY6.72MShares$11.6 Million0.27% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$8.21 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$7.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$5.96 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$5.45 Million0.03% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $97.2M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...